ArticleBlood advances2026

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Allison M Bock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.